Gyre Therapeutics Inc GYRE 深 滬
已收盤 02-06 16:00:00 美东时间
7.88
+0.370
+4.93%
華盛通- 最 高7.90
- 今 開7.64
- 成交量 4.75万股
- 最 低 7.575
- 昨 收 7.51
- 總市值 7.16亿
- 52周最高 13.75
- 市盈率 靜 163.83
- 換手率 0.05%
- 52周最低 6.11
- 委 比 83.04%
- 總股本 9089.04万
- 歷史最高 29271.2116
- 量 比 0.66
- 振 幅 4.33%
- 歷史最低 -19.80
- 每 手 1
- 風險率 1.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gyre Therapeutics Showcases Pipeline Progress and Market Leadership in Anti-Fibrotic Therapies
Gyre Therapeutics Showcases Pipeline Progress and Market Leadership in Anti-Fibrotic Therapies Gyre Therapeutics Inc. highlighted its leadership in the treatment of idiopathic pulmonary fibrosis (IPF) in China, with its product ETUARY® (pirfenidone) maintaining the largest market share for ten conse
01-28 06:02
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday
U.S. stocks were higher, with the Dow Jones index gaining more than 500 points ...
01-05 23:09
Earnings Scheduled For November 7, 2025
Companies Reporting Before The Bell • Kiora Pharmaceuticals (NASDAQ:KPRX) is pr...
2025-11-07 19:11
Gyre Therapeutics Q3 EPS $0.03 Beats $(0.02) Estimate, Sales $30.600M Miss $32.930M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.02) by 250 percent. This is a 200 percent increase over earnings of $0.01 per share from the
2025-11-07 19:07
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
Gyre Therapeutics subsidiary completes enrollment of 272 patients in China for Phase 3 trial of Pirfenidone capsules for pneumoconiosis, a chronic occupational lung disease. The trial, conducted at 18 research centers, aims to assess efficacy and safety over 52 weeks. Pneumoconiosis, caused by long-term dust exposure, has no approved targeted treatment in China, highlighting unmet medical need. Pirfenidone, an antifibrotic drug approved for idiop...
2025-10-15 11:00
美股大行评级 | 伯恩斯坦上调阿里巴巴目标价升至200美元；麦格理上调百度评级至"跑赢大市"，目标价升至176美元
今日重点评级关注：摩根大通：维持National Energy Services"超配"评级，目标价从10美元升至19美元；Piper Sandler：维持LENZ Therapeutics"超配"评级，目标价从51美元升至67美元
2025-10-13 11:26
Jefferies Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $16
Jefferies analyst Roger Song initiates coverage on Gyre Therapeutics (NASDAQ:GYRE) with a Buy rating and announces Price Target of $16.
2025-10-10 19:28
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Gyre Therapeutics announced that its management will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025, at 12:30 p.m. ET. The live webcast and replay will be available on Gyre’s website. Gyre focuses on developing therapies for fibrosis, particularly Hydronidone for liver fibrosis, and is expanding its pipeline in China through Gyre Pharmaceuticals.
2025-09-05 20:05
Gyre Therapeutics Appoints Dan Weng to Board
Gyre Therapeutics ( ($GYRE) ) has shared an update. On August 18, 2025, Gyre Th...
2025-08-22 19:28
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Gyre Therapeutics appoints Dan Weng, M.D., to its Board of Directors. Dr. Weng brings nearly four decades of experience in global clinical trials and holds leadership roles in several prominent CROs. Gyre, a biopharmaceutical company, focuses on developing therapies for organ fibrosis. Its flagship product, ETUARY® (Pirfenidone capsule), is a leading treatment for IPF in China. The company is also advancing Hydronidone and other therapies for var...
2025-08-22 11:00
